Insight Molecular Diagnostics Inc. (IMDX): Total Liabilities
$57.22M
As of 2025-12-31
$50.74M
As of 2026-06-30
-1.8%
3-year compound annual growth
+21.1%
5-year compound annual growth
+37.8%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $57.22M | +20.8% | 2026-03-26, Balance as of period end |
| 2024-12-31 | $47.35M | -3.9% | 2026-03-26, Balance as of period end |
| 2023-12-31 | $49.30M | -18.5% | 2025-03-24, Balance as of period end |
| 2022-12-31 | $60.50M | -35.9% | 2024-04-16, Balance as of period end |
| 2021-12-31 | $94.35M | +330.1% | 2023-04-12, Balance as of period end |
| 2020-12-31 | $21.94M | +143.2% | 2022-03-11, Balance as of period end |
| 2019-12-31 | $9.02M | +48.0% | 2021-03-19, Balance as of period end |
| 2018-12-31 | $6.09M | +4.9% | 2020-03-26, Balance as of period end |
| 2017-12-31 | $5.81M | +26.8% | 2019-04-01, Balance as of period end |
| 2016-12-31 | $4.58M | +98.1% | 2018-04-02, Balance as of period end |
| 2015-12-31 | $2.31M | n/a | 2017-02-27, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Insight Molecular Diagnostics Inc. (IMDX) | 2025-12-31 | $57.22M | +20.8% |
| Biomerica Inc (BMRA) | 2026-05-31 | $4.13M | +124.4% |
| Anbio Biotechnology (NNNN) | 2025-12-31 | $87.8K | -94.9% |
| Aspira Women's Health Inc. (AWHL) | 2025-12-31 | $12.39M | +53.8% |
| Volitionrx Ltd (VNRX) | 2025-12-31 | $42.49M | +19.7% |
| Celldex Therapeutics, Inc. (CLDX) | 2025-12-31 | $55.82M | +23.1% |
| Immucell Corp (ICCC) | 2025-12-31 | $15.48M | -12.0% |
| Alpha Teknova, Inc. (TKNO) | 2025-12-31 | $34.81M | -4.3% |
| Intellia Therapeutics, Inc. (NTLA) | 2025-12-31 | $170.73M | -46.5% |
Compare IMDX, BMRA, NNNN, AWHL side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗